Authors: Weber MS, Kappos L, Hauser SL, Nicholas JA, Schneble HM, Wang Q, Giovannoni G, Filippi M  

Published date: 11 October, 2023

Preserving patient fucntion, by optimally slowing disease progression, is important to people with MS and is a key treatment goal. The 10 year long-term impact of ocrelizumab on disability in patients with RMS and PPMS from the OLEs of the OPERA I/II (NCT) and ORARTORIO trials (NCT) respectively, are analysed. Disability progression, defined by several clinical measures, is reported in RMS and PPMS patients treated who initiated ocrelizumab treatment early, compared to delayed ocrelizumab treatment.

Authors: Hauser SL, Kappos L, Montalban X, Chognot C, Pasquarelli N, Kadner K, Pradhan A, Incera E, Wolinsky JS, El Azzouzi B

Published date: 11 October, 2023

The long-term consistency/stability of ocrelizumab (OCR) safety profile is demonstrated by reporting longer-term safety evaluations from OCR clinical trials and open-label extension (OLE) periods over a 10-year follow-up (up to November 2022). Saftey data, including type, severity and frequency of AEs, the risk of serious infections of IgG above and below lower limit of normal, and infusion-related reactions from pivotal Phase III trials and pooled OCR clinical trials, are presented including COVID-19 cases.

Authors: Braune S, Dirks P, Colloud S, Davies E, Wang Q, Heer Y, Zürcher M, Sun D, NTD Study Group

Published date: 12 October, 2023

Maintaining high persistence is important for controlling disease worsening and may result in more favourable outcomes. The 2- and 3-year persistence to OCR compared with other DMTs and the impact on outcomes in patients with MS from the German NTD MS registry is presented.